Olema Pharmaceuticals, Inc. (OLMA) — Financial statements
Income statement, balance sheet, and cash flow for Olema Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 158↑26.6% | 125↑44.6% | 86↑4.7% | 82↑61.0% | 51 | |
| General & Administrative Expenses | 21↑18.4% | 18↓5.7% | 19↓23.8% | 25↑21.2% | 20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 21↑18.4% | 18↓5.7% | 19↓23.8% | 25↑21.2% | 20 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 179↑25.6% | 142↑35.5% | 105↓1.9% | 107↑49.7% | 71 | |
| Total Costs & Expenses | 179↑25.6% | 142↑35.5% | 105↓1.9% | 107↑49.7% | 71 | |
| Operating Results | ||||||
| Operating Income | -179↓25.6% | -142↓35.5% | -105↑1.9% | -107↓49.7% | -71 | |
| Depreciation & Amortization | 0.49↑24.7% | 0.39↑4.2% | 0.38↑5.6% | 0.36↑119.0% | 0.16 | |
| EBITDA | -178↓25.6% | -142↓35.6% | -105↑1.9% | -107↓49.5% | -71 | |
| EBIT | -179↓25.6% | -142↓35.5% | -105↑1.9% | -107↓49.7% | -71 | |
| Interest & Other Income | ||||||
| Net Interest Income | 16↑27.9% | 13↑52.3% | 8↑273.7% | 2↑404.1% | 0.44 | |
| Interest Income | 16↑27.9% | 13↑52.3% | 8↑273.7% | 2↑404.1% | 0.44 | |
| Interest Expense | 0.00 | 0.00 | — | 0.00 | — | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 16↑27.1% | 13↑53.9% | 8↑277.4% | 2↑457.2% | 0.40 | |
| Income Before Tax | -162↓25.5% | -129↓34.0% | -97↑7.8% | -105↓47.4% | -71 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -162↓25.5% | -129↓34.0% | -97↑7.8% | -105↓47.4% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -162↓25.5% | -129↓34.0% | -97↑7.8% | -105↓47.4% | -71 | |
| Bottom-Line Net Income | -162↓25.5% | -129↓34.0% | -97↑7.8% | -105↓47.4% | -71 | |
| EPS (Basic) | -1.87↑15.0% | -2.20↓2.8% | -2.14↑18.3% | -2.62↓46.4% | -1.79 | |
| EPS (Diluted) | -1.87↑15.0% | -2.20↓2.8% | -2.14↑18.3% | -2.62↓46.4% | -1.79 | |
| Weighted Average Shares | 87↑48.1% | 59↑29.8% | 45↑13.1% | 40↑1.2% | 40 | |
| Weighted Average Diluted Shares | 87↑48.1% | 59↑29.8% | 45↑13.1% | 40↑1.2% | 40 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.